Results 101 to 110 of about 37,664 (239)

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

miRNA Profiling of Cholesteatoma‐Derived Exosomes Reveals Exosomal miR‐223‐3p and miR‐142‐5p as Potential Biomarkers for Acquired Middle Ear Cholesteatoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objectives Acquired cholesteatoma is an abnormal and invasive growth of keratinized squamous epithelial cells in the middle ear. The study aims to explore the role of exosomal miRNAs in the pathogenesis of acquired cholesteatoma and their potential in clinical application.
Qi Tang, Meng‐Yao Xie, Shu Wang, Zhi‐Yuan Wu, Zhi‐Jin Han, Chen Li, Shu‐Yi Wang, Yuan Cao, Yu‐Run Chen, Bin Wang, Ying‐Ying Shang, Xiao‐Wu Huang, Hua Yang   +12 more
wiley   +1 more source

532 Evaluating fibroblast growth factor receptor (FGFR) pathway mRNA expression and protein activation in cholangiocarcinoma tumors

Journal of Clinical and Translational Science
Objectives/Goals: Personalized cancer therapy based on genomic testing is advancing patient care. Genomic alterations in fibroblast growth factor receptor (FGFR) predict response to FGFR inhibitors; however, the role of RNA expression and protein ...
Leah Stein, Julie W. Reeser, Michele R. Wing, Eric Samorodnitsky, Anoosha Paruchuri, Amy Smith, Thuy Dao, Zachary Risch, Emanuel F. Petricoin, Sameek Roychowdhury   +9 more
doaj   +1 more source

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma

Cancer Discovery, 2019
ATP-competitive Fibroblast Growth Factor Receptor (FGFR) kinase inhibitors, including BGJ398 and Debio1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions.
L. Goyal, Lei Shi, Leah Y. Liu, F. Fece de la Cruz, Jochen K. Lennerz, Srivatsan Raghavan, Ignaty Leschiner, Liudmila Elagina, G. Siravegna, Raymond W. S. Ng, P. Vu, K. Patra, S. Saha, R. Uppot, Ron Arellano, Stephanie Reyes, T. Sagara, S. Otsuki, Brandon Nadres, Heather A. Shahzade, I. Dey‐Guha, Isobel J. Fetter, I. Baiev, Emily E. Van Seventer, Janet E. Murphy, C. Ferrone, Kenneth K. Tanabe, V. Deshpande, J. Harding, R. Yaeger, R. Kelley, A. Bardelli, A. Iafrate, William C. Hahn, C. Benes, David T. Ting, H. Hirai, G. Getz, D. Juric, Andrew X. Zhu, R. Corcoran, N. Bardeesy   +41 more
semanticscholar   +1 more source

Comparative Genomics and Functional Evidence for Convergent Adaptation to Hypoxia in Mammals

Integrative Zoology, EarlyView.
This study reveals convergent selection in mammals adapted to hypoxia. Functional assays demonstrate that amino acid mutations reduce oxidative stress, attenuate hypoxia‐induced injury, and modulate the hypoxia‐inducible transcription factor (HIF)‐driven hypoxic response.
Hao Dong, Chunxu Wang, Enqing Pei, Liang Zhao, Simin Chai, Ran Tian   +5 more
wiley   +1 more source

Recurrent FGFR2 and PIK3CA Mutations in Sialoblastoma

Head and Neck Pathology
Abstract Purpose Sialoblastoma is an extremely rare low-grade malignant salivary gland neoplasm that presents at birth or early infancy and has heterogeneous clinical behavior. Due to its rarity, the molecular landscape remains incompletely characterized.
Koo, Selene C., Ma, Jingqun, Tran, Quynh T., Alaggio, Rita, Stracuzzi, Alessandra, Chou, Pauline M., Wilkins, Benjamin J., Orr, Brent A., Malik, Faizan   +8 more
openaire   +3 more sources

TNFα modulates Fibroblast Growth Factor Receptor 2 gene expression through the pRB/E2F1 pathway: identification of a non-canonical E2F binding motif. [PDF]

PLoS ONE, 2013
Interactions between epithelium and mesenchyme during wound healing are not fully understood, but Fibroblast Growth Factors (FGFs) and their receptors FGFRs are recognized as key elements.
Sirio D'Amici, Simona Ceccarelli, Enrica Vescarelli, Ferdinando Romano, Luigi Frati, Cinzia Marchese, Antonio Angeloni   +6 more
doaj   +1 more source

Lower FGFR2 mRNA Expression and Higher Levels of FGFR2 IIIc in HER2-Positive Breast Cancer

Biology
Fibroblast growth factor receptor 2 (FGFR2) has been associated with breast cancer. We performed in silico analyses to investigate the FGFR2 mRNA expression and splice variants associated with breast cancer subtypes.
Thérèse Dix-Peek, Caroline Dickens, Juan Valcárcel, Raquel A. B. Duarte   +3 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Downregulation of KRTAP2‐3 Suppresses Proliferation and Tumor Formation of Oral Cancer Cells via Inactivation of KRAS Signals

Cancer Science, EarlyView.
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao, Zhijun Huang, Kazuki Takahashi, Haruka Ibi, Kohei Miyazono, Katarzyna A. Podyma‐Inoue, Tetsuro Watabe   +6 more
wiley   +1 more source